Calogero Cammà

Department of Health — Spain

Medicine · Health Sciences

79h-index20.0kcitations557works3.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Liver Disease Diagnosis and Treatment(359), Hepatitis C virus research(173), Liver Disease and Transplantation(118), Hepatocellular Carcinoma Treatment and Prognosis(110), Hepatitis B Virus Studies(59)

Publications555 total

The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort study
The Lancet Digital Health·2026Open Access
P0355 Prevalence of malnutrition and sarcopenia in hospitalized patients with inflammatory bowel diseases: a multimodal cross-sectional study
Journal of Crohn s and Colitis·2026
One-year Changes in Liver Stiffness Measurement, but not in Alanine Aminotransferase and Controlled Attenuation Parameter, Predict Long-term Liver Outcomes in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease
Clinical Gastroenterology and Hepatology·2026Open Access
Minimally Invasive Hepatic Resection Option for Access to the Waiting List of a Single Regional Transplant Center in Southern Italy: Entry and Dropout Flows’ Analysis
Journal of Clinical Medicine·2025Open Access
PHENO-RAG: An Artificial Intelligence tool for Guideline-Informed management decision of Hepatocellular Carcinoma
JHEP Reports·2025Open Access
Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study
JHEP Reports·2025Open Access
The ANTICIPATE-NASH Models Stratify Better the Risk of Clinical Events Than Histology in Metabolic Dysfunction-Associated Steatotic Liver Disease Patients With Advanced Chronic Liver Disease
Gastroenterology·2025Open Access
305P PHENO-RAG: A modular ensemble large language model framework for hepatocellular carcinoma with patient phenotyping and retrieval augmented generation-guided management
ESMO Real World Data and Digital Oncology·2025Open Access
354P A multimodal deep learning model for prediction of early progression in patients with advanced hepatocellular carcinoma treated with atezolizumab-bevacizumab
ESMO Real World Data and Digital Oncology·2025Open Access
Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis
˜The œLancet. Gastroenterology & hepatology·2025· 6 cited
Impact of First and Further Decompensation in Metabolic-Dysfunction Associated Compensated Advanced Chronic Liver Disease
Epidemiology Biostatistics and Public Health·2025Open Access
Diagnosed Patients With Chronic Hepatitis B and Delta Virus in Italy in 2024: An Estimation From a National Real‐World Database
Liver International·2025· 1 citedOpen Access
Post-TIPS paracentesis as a predictor of liver transplantation: a competing risks analysis
Digestive and Liver Disease·2025
Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma
JAMA Oncology·2025· 2 citedOpen Access
Establishing hepatic decompensation as a meaningful clinical outcome during systemic therapy for hepatocellular carcinoma
Journal of Hepatology·2025· 5 citedOpen Access
Clinical and molecular characterisation of primary refractoriness to atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma
2025Open Access
Impact of first and further decompensation in patients with compensated ACLD due to MASLD
Journal of Hepatology·2025· 2 citedOpen Access
FRI-089-YI Integrating quality of life and overall survival to quantify benefit from frontline systemic therapyoptions in unresectable/advanced hepatocellular carcinoma: a network meta-analysis
Journal of Hepatology·2025
WED-418-YI One-year changes in ALT and LSM, not in CAP, predict long-term liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease
Journal of Hepatology·2025
THU-408 The impact of first and further decompensation in patients with metabolic-dysfunction associated compensated advanced chronic liver disease
Journal of Hepatology·2025
page 1 of 28Next →

Frequent Co-authors

Antonio Craxı̀(39), Salvatore Petta(32), V. Di Marco(30), Daniela Cabibi(12), Giuseppe Cabibbo(10), Anna Licata(9), Vincenza Calvaruso(8), Marco Enea(7), Giulio Marchesini(7), Filippo Schepis(6), Erica Villa(6), Marco Barbàra(6), Fabio Marra(6), Marco Giunta(5), Vincent Wai‐Sun Wong(5), Victor de Lédinghen(5), Elisabetta Bugianesi(5), Stefania Grimaudo(5), Rosaria Maria Pipitone(5), Mario Cottone(4)